Evidence map›Paper›PMID 36841954›Full record

ArticleSchizophrenia bulletin2023

Is Clozapine-induced Weight Gain Dose-dependent? Results From a Prospective Cohort Study.

Marianna Piras, Jihane Chahma, Setareh Ranjbar, Nermine Laaboub, Claire Grosu, Kerstin Jessica Plessen, Armin von Gunten, Philippe Conus, Chin Bin Eap

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Schizophrenia bulletin, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Marianna PirasDepartment of Psychiatry, Unit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland.
Jihane ChahmaDepartment of Psychiatry, Unit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland.
Setareh RanjbarDepartment of Psychiatry, Center for Psychiatric Epidemiology and Psychopathology, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland.
Nermine LaaboubDepartment of Psychiatry, Unit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland.
Claire GrosuDepartment of Psychiatry, Unit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland.
Kerstin Jessica PlessenDepartment of Psychiatry, Service of Child and Adolescent Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland.
Armin von GuntenDepartment of Psychiatry, Service of Old Age Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland.
Philippe ConusDepartment of Psychiatry, Service of General Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland.
Chin Bin EapDepartment of Psychiatry, Unit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland.

Funding

Swiss National Research Foundation 320030-120686
6 · The paper itself

Abstract

backgroundAntipsychotic-induced metabolic adverse effects are risk factors for cardiometabolic comorbidities. Whether dose lowering could mitigate such effects remains unclear. The present study aims to investigate the associations between clozapine doses and modifications of weight, blood pressure, blood glucose, and lipid levels. STUDY

designLinear mixed-effects models of weight changes over 1 year and of variations of other metabolic parameters over 4 months were applied to a prospective cohort of 115 patients. Age- and sex-stratified analyses of weight changes were also performed. STUDY

resultsEach 100 mg dose increment of clozapine was associated on average with a +0.48% weight increase (P = .004) over 1 year of treatment. Weight increase was greater for treatment duration ≤3 vs >3 months (+0.84% and +0.47% per month, respectively, P < .001), with a significant association with the dose for durations >3 months (+0.54%, P = .004) and a trend for durations ≤3 months (+0.33%, P = .075). Dose increments of 100 mg were also associated with weight increases of +0.71% among adults (P = .001), +1.91% among the elderly (P < .001) and +1.32% among men (P < .001) with no associations among women (P = .62). Among young adults, weight change was positively associated with doses ≤300 mg/day (+2.19% per 100 mg, P = .001), whereas no association was found with doses >300 mg/day (P = .60). No significant effect of clozapine dose on other metabolic parameters was found.

conclusionsThis study reports a modest effect of clozapine dose increases on weight gain over 1 year with differences among age categories and sexes and no dose effect on other metabolic parameters over 4 months.

Indexed as

Antipsychotic AgentsClozapineAgedFemaleHumansInfantMaleProspective StudiesRisk FactorsWeight GainYoung AdultAntipsychotic AgentsClozapinedose dependencymetabolic adverse effectspsychotropic drugs

Identifiers

PMID36841954
PMCPMC10318871

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.